Identification

Name
Mecamylamine
Accession Number
DB00657  (APRD00458)
Type
Small Molecule
Groups
Approved
Description

A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. [PubChem]

Structure
Thumb
Synonyms
  • Versamine
Product Ingredients
IngredientUNIICASInChI Key
Mecamylamine hydrochloride4956DJR58O826-39-1PKVZBNCYEICAQP-UHFFFAOYSA-N
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mecamylamine HydrochlorideTablet2.5 mg/1OralNexgen Pharma, Inc.2013-03-19Not applicableUs
VecamylTablet2.5 mg/1OralManchester Pharmaceuticals2013-03-19Not applicableUs
VecamylTablet2.5 mg/1OralTuring Pharmaceuticals2013-03-19Not applicableUs
International/Other Brands
Inversine (Targacept)
Categories
UNII
6EE945D3OK
CAS number
60-40-2
Weight
Average: 167.2911
Monoisotopic: 167.167399677
Chemical Formula
C11H21N
InChI Key
IMYZQPCYWPFTAG-UHFFFAOYSA-N
InChI
InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3
IUPAC Name
N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
SMILES
CNC1(C)C2CCC(C2)C1(C)C

Pharmacology

Indication

For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension

Structured Indications
Pharmacodynamics

Mecamylamine is a potent, oral antihypertensive agent and ganglion blocker, and is a secondary amine. Mecamylamine is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. Mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced. Mecamylamine crosses the blood-brain and placental barriers.

Mechanism of action

Mecamylamine is a ganglionic blocker which prevents stimulation of postsynaptic receptors by acetylcholine released from presynaptic nerve endings. The hypotensive effect of Mecamylamine is attributed to reduction in sympathetic tone, vasodilation, and reduced cardiac output, and is primarily postural.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
inhibitor
Human
UNeuronal acetylcholine receptor subunit alpha-7Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-4Not AvailableHuman
UNeuronal acetylcholine receptor subunit beta-2Not AvailableHuman
Absorption

Mecamylamine is almost completely absorbed from the gastrointestinal tract

Volume of distribution
Not Available
Protein binding

40%

Metabolism
Not Available
Route of elimination

Mecamylamine is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine. Mecamylamine crosses the blood-brain and placental barriers.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Mecamylamine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Mecamylamine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Acebutolol.Approved
AclarubicinAclarubicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
AclidiniumMecamylamine may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Mecamylamine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Aliskiren.Approved, Investigational
AlmasilateThe serum concentration of Mecamylamine can be increased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Mecamylamine can be increased when it is combined with Aloglutamol.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Alphaprodine.Illicit
AlprenololMecamylamine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumThe serum concentration of Mecamylamine can be increased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Mecamylamine can be increased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Mecamylamine can be increased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Mecamylamine can be increased when it is combined with Aluminum hydroxide.Approved
AmbenoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ambenonium.Approved
AmbrisentanMecamylamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineMecamylamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinAmikacin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Mecamylamine.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Mecamylamine.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mecamylamine.Approved
Ammonium chlorideThe serum concentration of Mecamylamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Mecamylamine.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Mecamylamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Mecamylamine.Approved, Investigational
AmrubicinAmrubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Amyl Nitrite.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Mecamylamine.Approved
annamycinannamycin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Mecamylamine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Apraclonidine.Approved
ApramycinApramycin may increase the neuromuscular blocking activities of Mecamylamine.Experimental, Vet Approved
ArbekacinArbekacin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Mecamylamine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Mecamylamine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mecamylamine.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Mecamylamine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Mecamylamine.Approved, Vet Approved
AvanafilAvanafil may increase the antihypertensive activities of Mecamylamine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Azilsartan medoxomil.Approved
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Mecamylamine.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Mecamylamine.Experimental
BarbitalBarbital may increase the hypotensive activities of Mecamylamine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Mecamylamine.Approved
BekanamycinBekanamycin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mecamylamine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mecamylamine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Mecamylamine.Withdrawn
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mecamylamine.Approved
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine.Approved
BepridilMecamylamine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Mecamylamine.Approved
BethanidineBethanidine may increase the hypotensive activities of Mecamylamine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BietaserpineMecamylamine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostMecamylamine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Mecamylamine.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Mecamylamine can be increased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Mecamylamine can be increased when it is combined with Bismuth subnitrate.Experimental
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mecamylamine.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Mecamylamine.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Mecamylamine.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Mecamylamine.Approved, Investigational
Botulinum Toxin Type AMecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BMecamylamine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BQ-123Mecamylamine may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Mecamylamine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Mecamylamine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mecamylamine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mecamylamine.Approved, Investigational
BupranololMecamylamine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine butylbromide.Approved, Vet Approved
CadralazineMecamylamine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineMecamylamine may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateThe serum concentration of Mecamylamine can be increased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Mecamylamine can be increased when it is combined with Calcium silicate.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.Approved
CandesartanMecamylamine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Candesartan cilexetil.Approved
CandoxatrilMecamylamine may increase the hypotensive activities of Candoxatril.Experimental
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Mecamylamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Mecamylamine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Mecamylamine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carvedilol.Approved, Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mecamylamine.Approved, Investigational
CeliprololMecamylamine may increase the hypotensive activities of Celiprolol.Approved, Investigational
Chloramine-TThe risk or severity of adverse effects can be increased when Chloramine-T is combined with Mecamylamine.Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mecamylamine.Approved, Vet Approved
ChlorsulfaquinoxalineThe risk or severity of adverse effects can be increased when Chlorsulfaquinoxaline is combined with Mecamylamine.Investigational
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mecamylamine.Approved
CicletanineMecamylamine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Mecamylamine.Approved, Investigational
CimetropiumMecamylamine may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.Approved
ClindamycinClindamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Mecamylamine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Mecamylamine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Mecamylamine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Clopamide is combined with Mecamylamine.Experimental
CloranololMecamylamine may increase the hypotensive activities of Cloranolol.Experimental
ClorsulonThe risk or severity of adverse effects can be increased when Clorsulon is combined with Mecamylamine.Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Mecamylamine.Approved
CodeineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Mecamylamine.Approved, Investigational
CoumaphosThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Coumaphos.Vet Approved
CryptenamineMecamylamine may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Mecamylamine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mecamylamine.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Cyclothiazide is combined with Mecamylamine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mecamylamine.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Mecamylamine.Approved
DaunorubicinDaunorubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
DebrisoquinMecamylamine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Decamethonium.Approved
DelaprilMecamylamine may increase the hypotensive activities of Delapril.Experimental
DemecariumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Mecamylamine.Approved
DeserpidineMecamylamine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Mecamylamine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Mecamylamine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mecamylamine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dezocine.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Mecamylamine.Approved
DibekacinDibekacin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
DichlorvosThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Dichlorvos.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Mecamylamine.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Mecamylamine.Approved
diethylnorspermineMecamylamine may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineMecamylamine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the neuromuscular blocking activities of Mecamylamine.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Mecamylamine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dipyridamole.Approved
DistigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Donepezil.Approved
DorzolamideMecamylamine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mecamylamine.Approved
DoxorubicinDoxorubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Mecamylamine is combined with DPDPE.Experimental
DronabinolMecamylamine may increase the tachycardic activities of Dronabinol.Approved, Illicit
DuloxetineMecamylamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EchothiophateThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Edrophonium.Approved
EfonidipineMecamylamine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EluxadolineMecamylamine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Emepronium.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mecamylamine.Approved, Vet Approved
EnalaprilatMecamylamine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineMecamylamine may increase the hypotensive activities of Endralazine.Experimental
EpanololMecamylamine may increase the hypotensive activities of Epanolol.Experimental
EpirubicinEpirubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Eplerenone.Approved
EpoprostenolMecamylamine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Mecamylamine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Mecamylamine.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Mecamylamine.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etybenzatropine.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Felodipine.Approved, Investigational
FenoldopamMecamylamine may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Fenthion.Vet Approved
Ferulic acidMecamylamine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mecamylamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mecamylamine.Approved
FramycetinFramycetin may increase the neuromuscular blocking activities of Mecamylamine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Mecamylamine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Mecamylamine.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Mecamylamine.Approved
GeneticinGeneticin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
GentamicinGentamicin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the neuromuscular blocking activities of Mecamylamine.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.Approved
GlycopyrroniumMecamylamine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GPX-150GPX-150 may increase the neuromuscular blocking activities of Mecamylamine.Investigational
GuanabenzMecamylamine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelMecamylamine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineMecamylamine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineMecamylamine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Guanfacine.Approved, Investigational
GuanoclorMecamylamine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMecamylamine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMecamylamine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Mecamylamine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Mecamylamine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Mecamylamine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Huperzine A.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Mecamylamine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mecamylamine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mecamylamine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone.Approved, Illicit
HydrotalciteThe serum concentration of Mecamylamine can be increased when it is combined with Hydrotalcite.Experimental, Investigational
HydroxyfasudilThe risk or severity of adverse effects can be increased when Hydroxyfasudil is combined with Mecamylamine.Experimental
Hygromycin BHygromycin B may increase the neuromuscular blocking activities of Mecamylamine.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mecamylamine.Approved
IdarubicinIdarubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
IloprostIloprost may increase the hypotensive activities of Mecamylamine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mecamylamine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Mecamylamine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Mecamylamine.Approved
IndenololMecamylamine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminMecamylamine may increase the hypotensive activities of Indoramin.Withdrawn
INNO-206INNO-206 may increase the neuromuscular blocking activities of Mecamylamine.Investigational
IpidacrineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.Approved
IproclozideIproclozide may increase the hypotensive activities of Mecamylamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Mecamylamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Irbesartan.Approved, Investigational
IsepamicinIsepamicin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Mecamylamine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Mecamylamine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Mecamylamine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Mecamylamine.Investigational
KanamycinKanamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational, Vet Approved
KetanserinMecamylamine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ketobemidone.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mecamylamine.Approved
LacidipineMecamylamine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostMecamylamine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineMecamylamine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Mecamylamine.Approved, Investigational
LevodopaMecamylamine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Mecamylamine.Approved, Investigational
LincomycinLincomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
LinsidomineMecamylamine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Lisinopril.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Lofentanil.Illicit
LofexidineMecamylamine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Losartan.Approved
MacitentanMecamylamine may increase the hypotensive activities of Macitentan.Approved
MafenideThe risk or severity of adverse effects can be increased when Mafenide is combined with Mecamylamine.Approved, Vet Approved
MagaldrateThe serum concentration of Mecamylamine can be increased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineMecamylamine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mannitol.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mazaticol.Experimental
MebanazineMebanazine may increase the hypotensive activities of Mecamylamine.Withdrawn
MebutizideThe risk or severity of adverse effects can be increased when Mebutizide is combined with Mecamylamine.Experimental
MefloquineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mefloquine.Approved
MefrusideThe risk or severity of adverse effects can be increased when Mefruside is combined with Mecamylamine.Experimental
MemantineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methantheline.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methazolamide.Approved
MethenamineThe serum concentration of Mecamylamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethohexitalMethohexital may increase the hypotensive activities of Mecamylamine.Approved
MethoserpidineMecamylamine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Mecamylamine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Mecamylamine.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methylscopolamine bromide.Approved
MetipranololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mecamylamine.Approved, Investigational
MetrizamideMetrizamide may increase the neuromuscular blocking activities of Mecamylamine.Approved
MetyrosineMecamylamine may increase the hypotensive activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Mecamylamine.Approved, Investigational
MibefradilMecamylamine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicronomicinMicronomicin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
MinaprineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Mecamylamine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Mecamylamine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Mecamylamine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.Approved, Investigational
MoxonidineMecamylamine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineMecamylamine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneMecamylamine may increase the tachycardic activities of Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nadolol.Approved
NaftopidilMecamylamine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nalbuphine.Approved
NeamineNeamine may increase the neuromuscular blocking activities of Mecamylamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nebivolol.Approved, Investigational
NeomycinNeomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nesiritide.Approved, Investigational
NetilmicinNetilmicin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Mecamylamine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mecamylamine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nicomorphine.Experimental
NicorandilNicorandil may increase the hypotensive activities of Mecamylamine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nifedipine.Approved
NiguldipineMecamylamine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMecamylamine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Mecamylamine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mecamylamine.Approved
NitrendipineMecamylamine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Mecamylamine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mecamylamine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Normethadone.Approved, Illicit
ObinutuzumabMecamylamine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Mecamylamine.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mecamylamine.Approved, Investigational
OmapatrilatMecamylamine may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Orphenadrine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Otilonium.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxitropium.Investigational
OxprenololMecamylamine may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Mecamylamine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mecamylamine.Approved, Vet Approved
PancuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Papaverine.Approved
ParaoxonThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Paraoxon.Experimental
PargylinePargyline may increase the hypotensive activities of Mecamylamine.Approved
ParomomycinParomomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Mecamylamine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Mecamylamine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Mecamylamine.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Mecamylamine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Mecamylamine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Phenoperidine.Experimental
PhenoxybenzamineMecamylamine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Mecamylamine.Withdrawn
PhentolamineMecamylamine may increase the hypotensive activities of Phentolamine.Approved
PhthalylsulfathiazoleThe risk or severity of adverse effects can be increased when Phthalylsulfathiazole is combined with Mecamylamine.Experimental
PhysostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Physostigmine.Approved
PinacidilMecamylamine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Mecamylamine.Approved, Investigational
PipazethateThe risk or severity of adverse effects can be increased when Pipazethate is combined with Mecamylamine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipecuronium.Approved
PirarubicinPirarubicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Piritramide.Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Mecamylamine.Vet Approved
PirlindolePirlindole may increase the hypotensive activities of Mecamylamine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Mecamylamine.Withdrawn
Platelet Activating FactorMecamylamine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PlazomicinPlazomicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
PlicamycinPlicamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Mecamylamine.Approved
Potassium ChlorideMecamylamine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Mecamylamine.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Mecamylamine.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Mecamylamine.Approved
PrimidonePrimidone may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Mecamylamine.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Mecamylamine.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mecamylamine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Mecamylamine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Mecamylamine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Mecamylamine.Approved, Investigational
PuromycinPuromycin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
PyridostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pyridostigmine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinapril.Approved, Investigational
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Mecamylamine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Mecamylamine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mecamylamine.Approved
RamosetronMecamylamine may increase the constipating activities of Ramosetron.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Mecamylamine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Remifentanil.Approved
RemikirenMecamylamine may increase the hypotensive activities of Remikiren.Approved
RescinnamineMecamylamine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mecamylamine.Approved, Investigational
RibostamycinRibostamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
RilmenidineMecamylamine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Riociguat.Approved
RisperidoneMecamylamine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabMecamylamine may increase the hypotensive activities of Rituximab.Approved
RivastigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Mecamylamine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mecamylamine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Rosuvastatin is combined with Mecamylamine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Mecamylamine.Approved
SabarubicinSabarubicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mecamylamine.Approved
SafrazineSafrazine may increase the hypotensive activities of Mecamylamine.Withdrawn
SaprisartanMecamylamine may increase the hypotensive activities of Saprisartan.Experimental
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mecamylamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Mecamylamine.Approved, Investigational
SelegilineSelegiline may increase the hypotensive activities of Mecamylamine.Approved, Investigational, Vet Approved
SelexipagMecamylamine may increase the hypotensive activities of Selexipag.Approved
SetrobuvirThe risk or severity of adverse effects can be increased when Setrobuvir is combined with Mecamylamine.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mecamylamine.Approved, Vet Approved
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Mecamylamine.Approved, Investigational
Silver sulfadiazineThe risk or severity of adverse effects can be increased when Silver sulfadiazine is combined with Mecamylamine.Approved, Vet Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Mecamylamine.Approved
SisomicinSisomicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
SitaxentanMecamylamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Mecamylamine can be increased when it is combined with Sodium bicarbonate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Mecamylamine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Solifenacin.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mecamylamine.Approved
SP1049CSP1049C may increase the neuromuscular blocking activities of Mecamylamine.Investigational
SpectinomycinSpectinomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational, Vet Approved
SpiraprilMecamylamine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mecamylamine.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Mecamylamine.Approved, Investigational
StreptomycinStreptomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
StreptozocinStreptozocin may increase the neuromuscular blocking activities of Mecamylamine.Approved
SuccinylsulfathiazoleThe risk or severity of adverse effects can be increased when Succinylsulfathiazole is combined with Mecamylamine.Experimental
SufentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.Approved, Investigational
SulfacetamideThe risk or severity of adverse effects can be increased when Sulfacetamide is combined with Mecamylamine.Approved
SulfachlorpyridazineThe risk or severity of adverse effects can be increased when Sulfachlorpyridazine is combined with Mecamylamine.Vet Approved
SulfacytineThe risk or severity of adverse effects can be increased when Sulfacytine is combined with Mecamylamine.Approved
SulfadiazineThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Mecamylamine.Approved, Vet Approved
SulfadicramideThe risk or severity of adverse effects can be increased when Sulfadicramide is combined with Mecamylamine.Experimental
SulfadimethoxineThe risk or severity of adverse effects can be increased when Sulfadimethoxine is combined with Mecamylamine.Approved, Vet Approved
SulfadoxineThe risk or severity of adverse effects can be increased when Sulfadoxine is combined with Mecamylamine.Approved, Investigational
SulfaethoxypyridazineThe risk or severity of adverse effects can be increased when Sulfaethoxypyridazine is combined with Mecamylamine.Vet Approved
SulfaguanidineThe risk or severity of adverse effects can be increased when Sulfaguanidine is combined with Mecamylamine.Experimental
SulfaisodimidineThe risk or severity of adverse effects can be increased when Sulfaisodimidine is combined with Mecamylamine.Experimental
SulfamerazineThe risk or severity of adverse effects can be increased when Sulfamerazine is combined with Mecamylamine.Approved, Vet Approved
SulfameterThe risk or severity of adverse effects can be increased when Sulfameter is combined with Mecamylamine.Approved
SulfamethazineThe risk or severity of adverse effects can be increased when Sulfamethazine is combined with Mecamylamine.Approved, Investigational, Vet Approved
SulfamethizoleThe risk or severity of adverse effects can be increased when Sulfamethizole is combined with Mecamylamine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Mecamylamine.Approved
SulfamethoxypyridazineThe risk or severity of adverse effects can be increased when Sulfamethoxypyridazine is combined with Mecamylamine.Experimental
SulfametopyrazineThe risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Mecamylamine.Approved, Withdrawn
SulfamoxoleThe risk or severity of adverse effects can be increased when Sulfamoxole is combined with Mecamylamine.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine.Approved
SulfanitranThe risk or severity of adverse effects can be increased when Sulfanitran is combined with Mecamylamine.Vet Approved
SulfaphenazoleThe risk or severity of adverse effects can be increased when Sulfaphenazole is combined with Mecamylamine.Approved
SulfapyridineThe risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine.Approved
SulfaquinoxalineThe risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Mecamylamine.Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mecamylamine.Approved
SulfathiazoleThe risk or severity of adverse effects can be increased when Sulfathiazole is combined with Mecamylamine.Approved, Vet Approved
SulfathioureaThe risk or severity of adverse effects can be increased when Sulfathiourea is combined with Mecamylamine.Experimental
SulfatolamideThe risk or severity of adverse effects can be increased when Sulfatolamide is combined with Mecamylamine.Experimental
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Mecamylamine.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Mecamylamine.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Mecamylamine.Approved, Investigational
TacrineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Mecamylamine.Approved, Investigational
TalinololMecamylamine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Mecamylamine.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tapentadol.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Telmisartan.Approved, Investigational
TemocaprilMecamylamine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Terazosin.Approved
TerlipressinMecamylamine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineMecamylamine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Mecamylamine.Approved, Investigational, Withdrawn
TheodrenalineMecamylamine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mecamylamine.Approved, Withdrawn
TiboloneMecamylamine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenMecamylamine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Mecamylamine.Approved
TiotropiumMecamylamine may increase the anticholinergic activities of Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tizanidine.Approved
TobramycinTobramycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
TolazolineMecamylamine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mecamylamine.Approved, Withdrawn
TolonidineMecamylamine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Mecamylamine.Approved
TolterodineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Mecamylamine.Approved
TramadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mecamylamine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Mecamylamine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Mecamylamine.Approved
TravoprostMecamylamine may increase the hypotensive activities of Travoprost.Approved
TreprostinilMecamylamine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Mecamylamine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Mecamylamine.Approved
TrichlorfonThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Mecamylamine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mecamylamine.Approved
TrimazosinMecamylamine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Trimethaphan.Approved, Investigational
TromethamineThe serum concentration of Mecamylamine can be increased when it is combined with Tromethamine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Mecamylamine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Mecamylamine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Mecamylamine.Approved, Investigational
UmeclidiniumMecamylamine may increase the anticholinergic activities of Umeclidinium.Approved
UnoprostoneMecamylamine may increase the hypotensive activities of Unoprostone.Approved
UrapidilMecamylamine may increase the hypotensive activities of Urapidil.Investigational
ValrubicinValrubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mecamylamine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Mecamylamine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.Approved
VincamineMecamylamine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineMecamylamine may increase the hypotensive activities of Vinpocetine.Investigational
XipamideThe risk or severity of adverse effects can be increased when Xipamide is combined with Mecamylamine.Experimental
XylometazolineMecamylamine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Mecamylamine.Approved, Vet Approved
ZofenoprilMecamylamine may increase the hypotensive activities of Zofenopril.Experimental
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
ZorubicinZorubicin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,831,027.

General References
Not Available
External Links
Human Metabolome Database
HMDB14795
KEGG Compound
C07511
PubChem Compound
4032
PubChem Substance
46508607
ChemSpider
3892
BindingDB
50061565
ChEBI
6706
ChEMBL
CHEMBL267936
Therapeutic Targets Database
DAP000027
PharmGKB
PA450334
IUPHAR
3990
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mecamylamine
ATC Codes
C02BB01 — Mecamylamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAutistic Disorder / Pervasive Developmental Disorder NOS1
1CompletedTreatmentSmoking1
1, 2Active Not RecruitingTreatmentChronic Orthostatic Intolerance / Tachycardia1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentDepression / Major Depressive Disorder (MDD)1
2CompletedTreatmentDepressive Disorders1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentSmoking1
2TerminatedTreatmentMacular Degeneration1
3CompletedTreatmentAlcohol Dependence / Depression1
Not AvailableCompletedBasic ScienceCognition / Magnetic Resonance Imaging (MRI) / Mecamylamine / Nicotine1
Not AvailableCompletedTreatmentCognition in Schizophrenia1

Pharmacoeconomics

Manufacturers
  • Targacept inc
Packagers
Dosage forms
FormRouteStrength
TabletOral2.5 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)249 with decompositionU.S. Patent 2,831,027.
boiling point (°C)72 °C at 4.00E+00 mm HgPhysProp
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.124 mg/mLALOGPS
logP3.13ALOGPS
logP2.37ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)10.88ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity51.83 m3·mol-1ChemAxon
Polarizability20.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9566
Blood Brain Barrier+0.9771
Caco-2 permeable+0.611
P-glycoprotein substrateNon-substrate0.6815
P-glycoprotein inhibitor INon-inhibitor0.8271
P-glycoprotein inhibitor IINon-inhibitor0.889
Renal organic cation transporterNon-inhibitor0.7727
CYP450 2C9 substrateNon-substrate0.7864
CYP450 2D6 substrateNon-substrate0.7207
CYP450 3A4 substrateSubstrate0.5884
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9054
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7435
Ames testNon AMES toxic0.9315
CarcinogenicityNon-carcinogens0.8757
BiodegradationNot ready biodegradable0.6954
Rat acute toxicity2.3843 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9676
hERG inhibition (predictor II)Non-inhibitor0.8756
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0900000000-d1e9fe76d5bc86bef4e9
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001r-9700000000-9505ece9327e31f47ce0
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-9000000000-e4663d1da4e4bc059200
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-9000000000-c6fd00cf5fa5e7d227e5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-003r-9000000000-e197ecfa004b426aeb2b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001r-9500000000-4e031bcaa41c1a77d136

Taxonomy

Description
This compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Bicyclic monoterpenoids
Alternative Parents
Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Bicyclic monoterpenoid / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aliphatic homopolycyclic compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
primary aliphatic amine (CHEBI:6706)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, Bevins RA: Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine. Pharmacol Biochem Behav. 2009 Dec;94(2):319-28. doi: 10.1016/j.pbb.2009.09.012. Epub 2009 Sep 22. [PubMed:19778551]
  5. Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR: Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7. [PubMed:12080428]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Briggs CA, McKenna DG, Monteggia LM, Touma E, Roch JM, Arneric SP, Gopalakrishnan M, Sullivan JP: Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. Eur J Pharmacol. 1999 Feb 5;366(2-3):301-8. [PubMed:10082212]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ: Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol. 2003 Dec;64(6):1283-94. [PubMed:14645658]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNB2
Uniprot ID
P17787
Uniprot Name
Neuronal acetylcholine receptor subunit beta-2
Molecular Weight
57018.575 Da
References
  1. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ: Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol. 2003 Dec;64(6):1283-94. [PubMed:14645658]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 17:16